Anthelmintic tablet for patients 6 years of age and older.
EGATEN™ (triclabendazole, Novartis)
Indications: treatment of fascioliasis in patients six years of age or older
Dosage:
Contraindications: known hypersensitivity to triclabendazole, other benzimidazole derivatives or any of the excipients in EGATEN
FDA Issues CRL for Heplisav-B in Adults With ESRD on Hemodialyis
May 14th 2024Dynavax plans to meet with the FDA to discuss how the company can provide additional data to support the approval of its 4-dose Heplisav-B regimen and expand protection for adults with end-stage renal disease (ESRD) on hemodialysis.